Background. IMPAACT P1066 is a phase I/II open-label multicenter trial to evaluate pharmacokineti... more Background. IMPAACT P1066 is a phase I/II open-label multicenter trial to evaluate pharmacokinetics, safety, tolerability, and efficacy of multiple raltegravir formulations in human immunodeficiency virus (HIV)-infected youth. Methods. Dose selection for each cohort (I: 12 to <19 years; II: 6 to <12 years; and III: 2 to <6 years) was based on review of short-term safety (4 weeks) and intensive pharmacokinetic evaluation. Safety data through weeks 24 and 48, and grade ≥3 or serious adverse events (AEs) were assessed. The primary virologic endpoint was achieving HIV RNA <400 copies/mL or ≥1 log 10 reduction between baseline and week 24. Results. The targeted pharmacokinetic parameters (AUC 0-12h and C 12h) were achieved for each cohort, allowing dose selection for 2 formulations. Of 96 final dose subjects, there were 15 subjects with grade 3 or higher clinical AEs (1 subject with drug-related [DR] psychomotor hyperactivity and insomnia); 16 subjects with grade 3 or higher laboratory AEs (1 with DR transaminase elevation); 14 subjects with serious clinical AEs (1 with DR rash); and 1 subjects with serious laboratory AEs (1 with DR transaminase increased). There were no discontinuations due to AEs and no DR deaths. Favorable virologic responses at week 48 were observed in 79.1% of patients, with a mean CD4 increase of 156 cells/µL (4.6%). Conclusions. Raltegravir as a film-coated tablet 400 mg twice daily (6 to <19 years, and ≥25 kg) and chewable tablet 6 mg/kg (maximum dose 300 mg) twice daily (2 to <12 years) was well tolerated and showed favorable virologic and immunologic responses. Clinical Trials Registration. NCT00485264.
Los Estados Partes en la presente Convención, Teniendo presente que desde antiguos tiempos los pu... more Los Estados Partes en la presente Convención, Teniendo presente que desde antiguos tiempos los pueblos de todas las naciones han reconocido el estatuto de los funcionarios diplomáticos, Teniendo en cuenta los propósitos y principios de la Carta de las Naciones Unidas relativos a la igualdad soberana de los Estados, al mantenimiento de la paz y de la seguridad internacionales y al fomento de las relaciones de amistad entre las naciones,
Background. IMPAACT P1066 is a phase I/II open-label multicenter trial to evaluate pharmacokineti... more Background. IMPAACT P1066 is a phase I/II open-label multicenter trial to evaluate pharmacokinetics, safety, tolerability, and efficacy of multiple raltegravir formulations in human immunodeficiency virus (HIV)-infected youth. Methods. Dose selection for each cohort (I: 12 to <19 years; II: 6 to <12 years; and III: 2 to <6 years) was based on review of short-term safety (4 weeks) and intensive pharmacokinetic evaluation. Safety data through weeks 24 and 48, and grade ≥3 or serious adverse events (AEs) were assessed. The primary virologic endpoint was achieving HIV RNA <400 copies/mL or ≥1 log 10 reduction between baseline and week 24. Results. The targeted pharmacokinetic parameters (AUC 0-12h and C 12h) were achieved for each cohort, allowing dose selection for 2 formulations. Of 96 final dose subjects, there were 15 subjects with grade 3 or higher clinical AEs (1 subject with drug-related [DR] psychomotor hyperactivity and insomnia); 16 subjects with grade 3 or higher laboratory AEs (1 with DR transaminase elevation); 14 subjects with serious clinical AEs (1 with DR rash); and 1 subjects with serious laboratory AEs (1 with DR transaminase increased). There were no discontinuations due to AEs and no DR deaths. Favorable virologic responses at week 48 were observed in 79.1% of patients, with a mean CD4 increase of 156 cells/µL (4.6%). Conclusions. Raltegravir as a film-coated tablet 400 mg twice daily (6 to <19 years, and ≥25 kg) and chewable tablet 6 mg/kg (maximum dose 300 mg) twice daily (2 to <12 years) was well tolerated and showed favorable virologic and immunologic responses. Clinical Trials Registration. NCT00485264.
Los Estados Partes en la presente Convención, Teniendo presente que desde antiguos tiempos los pu... more Los Estados Partes en la presente Convención, Teniendo presente que desde antiguos tiempos los pueblos de todas las naciones han reconocido el estatuto de los funcionarios diplomáticos, Teniendo en cuenta los propósitos y principios de la Carta de las Naciones Unidas relativos a la igualdad soberana de los Estados, al mantenimiento de la paz y de la seguridad internacionales y al fomento de las relaciones de amistad entre las naciones,
Uploads
Papers by Matias Acevedo